Investor Alert: Pomerantz Law Firm Investigates Claims Against Ultragenyx Pharmaceutical Inc.
Pomerantz LLP is investigating potential securities fraud or other unlawful business practices involving Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and certain of its officers and directors, on behalf of investors. The investigation follows a September 2026 press release announcing that the Phase 3 Aspire study for apazunersen in Angelman syndrome did not meet primary or key secondary endpoints. Following this news, Ultragenyx's stock price dropped significantly by $11.68 per share (44.03%) to close at $14.85 on September 3, 2026. Pomerantz LLP is a well-known law firm specializing in corporate and securities litigation with offices across the U.S., London, Paris, and Tel Aviv.
Tickers: $RARE
Topics: clinical_trial_results pharmaceuticals stock_price_drop